Cadila Healthcare API manufacturing unit gets EIR from USFDA; stock down 1%

The EIR report stated that the classification of the facility is ’No Action Indicated (NAI)’, the company added.

Dec 06, 2019 06:12 IST India Infoline News Service

Cadila Healthcare
Shares of Cadila Healthcare slipped 1% on the BSE in the noon trade after its API manufacturing facility located at Dabhasa, Gujarat received an Establishment Inspection Report.

“The company’s API manufacturing facility located at Dabhasa, Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from October 7-11, 2019,” the company said in the filing.

The EIR report stated that the classification of the facility is ’No Action Indicated (NAI)’, the company added.

Cadila Healthcare Ltd is currently trading at Rs255.15, down by Rs2.85 or 1.1% from its previous closing of Rs258 on the BSE.

The scrip opened at Rs257.85 and has touched a high and low of Rs260.60 and Rs253.25 respectively.

Related Story